Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg) [3]

American Journal of Medical Genetics, Part A

Volumn 140, Issue 20, 2006, Pages 2245-2247

  Andreou, Andréas ^a,b   Lamy, Aude ^a   Layet, Valérie ^b   Cailliez, Daniel ^b   Gobet, Françoise ^a   Pfister, Christian ^a   Menard, Michel ^b   Frebourg, Thierry ^a,c  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b LE HAVRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PROLINE;

ACROCEPHALOSYNDACTYLY; BLADDER CARCINOMA; CASE REPORT; CLINICAL FEATURE; CYSTOSCOPY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FGFR2 GENE; GENE; GENE MUTATION; GENE SEQUENCE; HEMATURIA; HISTOPATHOLOGY; HUMAN; INTRAVENOUS PYELOGRAPHY; LETTER; ONSET AGE; PAPILLARY CARCINOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; SYMPTOM;

ACROCEPHALOSYNDACTYLIA; CARCINOMA, PAPILLARY; CHILD, PRESCHOOL; FEMALE; HUMANS; MUTATION, MISSENSE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; URINARY BLADDER NEOPLASMS;

EID: 33749472259     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31430     Document Type: Letter

References (16)

1. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, Gil Diez de Medina S. 2003. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108-8112.
2. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, Van der Kwast T, Thiery JP, Radvanyi F. 2001. Frequent FGFR3 mutations in papillary non invasive bladder (pTa) tumors. Am J Pathol 158:1955-1959.
3. Blank CE. 1960. Apert's syndrome (a type of acrocephalosyndactyly)- Observations on a British series of thirty-nine cases. Ann Hum Gent 24:151-164.
4. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20.
5. Cohen MM Jr. 2000. Apert syndrome. In: Cohen MM Jr, MacLean RE, editors. Craniosynostosis: Diagnosis, evaluation, and management, 2nd edition. New York: Oxford University Press, p 316-353.
6. Cohen MM Jr. 2003. Neoplasms associated with alterations in fibroblast growth factor receptors. Am J Med Genet Part A 119A:97-100.
7. Cohen M, Ghosh L, Schafer E. 1987. Congenital embryonal rhabdomyosarcoma of the hand and Apert syndrome. J Hand Surg 12A:614-617.
8. Cohen MM Jr, Kreiborg S. 1993. Visceral anomalies in the Apert syndrome. Am J Med Genet 45:758-760.
9. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S. GortonM, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LHJ, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595.
10. Hansen RM, Goriely A, Wall SA, Roberts IS, Wilkie AO. 2005. Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: Investigating a potential link. J Pathol 207:27-31.
11. Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG. 2000. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 60:4049-4052.
12. Jang JH, Shin KH, Part JG. 2001. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61:3541-3543.
13. Kimura T, Suzuku H, Ohashi T, Asano K, Kiota H, Eto Y. 2001. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92:2555-2561.
14. Sibley K, Stern P, Knowles MA. 2001. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene 20:4416-4418.
15. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC. 2003. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912-1921.
16. Wu B, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR. 2000. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 19:5543-5546.